Dianthus Therapeutics Financial Statements
NASDAQ: DNTHHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Dianthus Therapeutics revenue and earnings
In fiscal 2025, Dianthus Therapeutics generated $2.0 million in revenue, down 67.3% from fiscal 2024, the first decline in the 10 years shown. Dianthus Therapeutics reported a net loss of $162.3 million, compared with a loss of $85.0 million a year earlier. Operating margin was -8739.3%.
Diluted earnings per share came in at -$4.20.
Summary generated from market data by MetaCap's automated system. Methodology
Dianthus Therapeutics income statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.04M | 6.24M | 2.83M | — | — | — | 0 | 0 | 0 | 0 |
| Revenue growth (YoY) | -67.35% | +120.63% | — | — | — | — | — | — | — | — |
| Operating Expenses | 179.97M | 108.10M | 51.00M | 36.12M | 74.69M | 78.70M | 82.97M | 59.96M | 35.73M | 9.27M |
| Research & Development | 145.64M | 83.11M | 32.84M | 29.38M | 46.77M | 50.62M | 59.21M | 41.34M | 27.90M | 5.78M |
| Operating Income | -177.93M | -101.86M | -48.17M | -29.70M | -74.69M | -78.70M | -82.97M | -59.96M | -35.73M | -9.27M |
| Interest Expense | — | — | — | — | — | — | — | — | — | 163.00K |
| Other Income (Expense) | 15.60M | 16.89M | 4.62M | 1.23M | — | — | — | 2.45M | 236.00K | -163.00K |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | -162.34M | -84.97M | -43.55M | -28.48M | -71.14M | -74.94M | -76.77M | -57.52M | -35.49M | -9.43M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — |
| EPS (Basic) | -4.20 | -2.55 | -8.45 | -32.57 | -1.29 | -1.71 | -2.07 | -3.13 | -19.12 | -65.15 |
| EPS (Diluted) | -4.20 | -2.55 | -8.45 | -32.57 | -1.29 | -1.71 | -2.07 | -3.13 | -19.12 | -65.15 |
| Shares Outstanding (Basic) | 38.62M | 33.31M | 5.15M | 874.23K | 54.95M | 43.92M | 37.01M | 18.39M | 1.86M | 149.41K |
| Shares Outstanding (Diluted) | 38.62M | 33.31M | 5.15M | 874.23K | 54.95M | 43.92M | 37.01M | 18.39M | 1.86M | 149.41K |
| EBITDA | -177.82M | -101.77M | -48.11M | -27.78M | -72.67M | -76.72M | -81.13M | -59.09M | -35.35M | -9.26M |
| Operating Margin | -8739.34% | -1633.74% | -1704.67% | — | — | — | — | — | — | — |
| Net Margin | -7973.33% | -1362.77% | -1541.22% | — | — | — | — | — | — | — |
This table shows 10 annual periods of Dianthus Therapeutics's income statement, from FY 2025 back to FY 2016, across 15 line items including revenue, operating expenses, research & development. Values in USD; B = billions, M = millions. Fiscal periods follow DNTH's reporting calendar. What is a income statement?